Cerus Co. (NASDAQ:CERS – Get Free Report) insider Richard J. Benjamin sold 18,949 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $1.45, for a total value of $27,476.05. Following the transaction, the insider now owns 715,850 shares of the company’s stock, valued at approximately $1,037,982.50. The trade was a 2.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Cerus Stock Performance
Shares of CERS stock remained flat at $1.45 during midday trading on Monday. The company’s stock had a trading volume of 1,979,196 shares, compared to its average volume of 1,302,541. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.54. The company has a 50-day simple moving average of $1.72 and a 200 day simple moving average of $1.76. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The firm has a market cap of $269.40 million, a price-to-earnings ratio of -13.18 and a beta of 1.56.
Cerus (NASDAQ:CERS – Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The firm had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. As a group, equities analysts expect that Cerus Co. will post -0.08 EPS for the current fiscal year.
Institutional Trading of Cerus
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.
Get Our Latest Research Report on CERS
About Cerus
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Read More
- Five stocks we like better than Cerus
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Can TikTok Stock Picks Really Make You Rich?
- 3 Warren Buffett Stocks to Buy Now
- The “Quality” Rotation: Back to Basics Investing
- Why Invest in High-Yield Dividend Stocks?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.